Introduction
============

Gastrointestinal stromal tumors (GISTs) are the most frequently observed intra-abdominal sarcomas and occur primarily from the gastrointestinal tract or less commonly from the mesentery and retroperitoneum ([@b1-ol-0-0-9003]--[@b4-ol-0-0-9003]). The majority of cases are characterized by an activated mutation of the receptor tyrosine kinase, KIT ([@b5-ol-0-0-9003]), or platelet-derived growth factor receptor α ([@b6-ol-0-0-9003]). Patients with advanced GISTs were successfully treated with imatinib mesylate, a potent tyrosine kinase inhibitor (TKI), with a median overall survival period of 5--6 years. However, acquired resistance mainly resulting from secondary mutation inevitably developed within 2--3 years after treatment ([@b7-ol-0-0-9003],[@b8-ol-0-0-9003]). Salvage TKIs, including sunitinib maleate and regorafenib, yielded less satisfactory results ([@b9-ol-0-0-9003],[@b10-ol-0-0-9003]). Therefore, novel biomarkers or treatment targets for TKI-refractory cases are required.

Genes that regulate cell cycle have a crucial role in predicting a prognosis for soft tissue sarcomas ([@b11-ol-0-0-9003],[@b12-ol-0-0-9003]). By reanalyzing available expression profiling data on GISTs ([@b13-ol-0-0-9003]), our group has previously identified gene sets, including the cell cycle process or its regulation, that were strongly associated with the risk of recurrence. Aurora kinase A (AURKA) was identified as an independent poor prognostic marker for GIST recurrence ([@b14-ol-0-0-9003]). A subsequent study by the authors confirmed that AURKA may also serve as an independent unfavorable marker for predicting disease progression or mortality from advanced GISTs and as a potential treatment target for GISTs ([@b15-ol-0-0-9003]). The aforementioned studies have implicated the crucial role of genes that regulate cell cycle in sarcomas and GISTs. In the present study, the prognostic effect of genes involved in cell cycle regulation in GISTs was examined.

Patients and methods
====================

### Bioinformatic analysis

In a previous study by the authors ([@b14-ol-0-0-9003]), using gene set enrichment analysis (GSEA; downloaded from <http://www.broadinstitute.org/gsea/index.jsp>), 32 cases in Gene Expression Omnibus dataset GSE8167, previously reported by Yamaguchi *et al* ([@b13-ol-0-0-9003]), were classified into two risk groups with distinct recurrence-free survival (RFS) and expression profiles according to the modified criteria of Yen *et al* ([@b14-ol-0-0-9003]) from the Armed Forces Institute of Pathology (AFIP). Of the 715 Gene Ontology (GO) gene sets, which exhibited differential expression between two risk groups, 316 were upregulated in the high-risk phenotype. To identify significant genes and pathways in these gene sets, leading edge analysis (LEA) was used in GSEA to examine genes in the leading edge subsets of the top 10 enriched gene sets ([@b14-ol-0-0-9003]). It was hypothesized that genes that appear in multiple subsets are more likely to be of interest than those that appear in only one subset. The obtained gene list was uploaded to the Pathway Interaction Database (PID; <http://wiki.nci.nih.gov/pages/viewpage.action?pageId=315491760>) for analyzing the distribution of the molecules within predefined pathways. The query uses a hypergeometric distribution, which models the probability of observing k genes from a cluster of n genes (network frequency) by chance in a pathway or biological process category containing m genes from a total genome size of N genes (genome frequency), to compute the probability that each pathway in the database is hit by molecules in the list. It then returns a list of pathways ordered by P-value, which indicates the probability that the specific pathway is enriched by chance ([@b16-ol-0-0-9003]). The expression level of each individual probe was obtained using Z-score transformation. For genes encoded by more than one probe, average Z-score values were used for comparison. The differences among the risk groups were subsequently compared using the t-test.

### Tumor samples for immunohistochemistry study

This study is a retrospective study. A total of 141 patients who received the diagnosis of GIST between 1989 and 2008 at Chang Gung Memorial Hospital (Taoyuan, Taiwan) were enrolled for immunohistochemistry (IHC) study. These cases were reported previously ([@b14-ol-0-0-9003]); they were patients with localized GIST who had received surgical excision only with no adjuvant imatinib therapy, had formalin-fixed paraffin-embedded tissues available for IHC study and were regularly followed up with appropriate radiological imaging evaluations at Chang Gung Memorial Hospital. The protocols for tumor sample collection and clinical record review were approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB no. 98-0352B), and all patients had provided informed consent for the use of their tissues and clinical data in research. All identifying information of individual patient was removed.

### IHC staining of cell cycle regulation genes in GIST

A 4-µm section of each specimen was stained for selected proteins. Primary antibodies used in the present study were anti-Aurora (catalog no. ANB100-212; 1:1,500) and anti-polo-like kinase 1 (PLK1; catalog no. NBP1-02851; 1:100) antibodies from Novus Biologicals, (LLC, Littleton, CO, USA) as well as anti-cell division cycle 25C (CDC25C; catalog no. ab66235; 1:100), anti-budding uninhibited by benzimidazoles (BUB1; catalog no. ab4636; 1:100), and anti-targeting protein for Xklp2 (TPX2; catalog no. ab32795; 1:1,000) antibodies from Abcam, (Cambridge, UK). The antibodies were diluted as suggested and added to the slides, which were incubated overnight at 4°C. The slides were then washed three times for 5 min each in a mixture of tris-buffered saline and Polysorbate 20 (the mixture is referred to as 'TBST' hereafter) prior to visualization using the LSAB2 system, Peroxidase (K0675; DAKO A/S). The control slides were incubated with the secondary antibody alone \[also contained within the LSAB2 system, Peroxidase (K0675; DAKO A/S\]. After 3 TBST washes for 5 min for each wash, the slides were mounted and blindly analyzed under microscopy by the authors. Immunostaining was scored.

For the assessment of IHC staining, the percentage of stained target cells was evaluated in 10 optical microscope fields per tissue section (magnification, ×400) and the average staining percentage was calculated. For BUB1 and CDC25C, only nuclear staining was considered positive. Staining intensity was scored as 1 (mild), 2 (moderate), or 3 (intense). H-scores were calculated as the percentage of positive staining (0--100%) × the corresponding staining intensity (0--3) ([@b17-ol-0-0-9003]). The specimens with low and high H-scores were classified as having low and high IHC expression, respectively (cutoff value of H-scores: AURKA=60, TPX2=40, BUB1=50, CDC25C=50, and PLK1=60; [Fig. 1](#f1-ol-0-0-9003){ref-type="fig"}).

### Statistical and survival analysis

The associations between clinicopathological variables and IHC staining patterns of cell cycle regulation genes were analyzed using the χ^2^ test or Fisher\'s exact test for univariate analysis and using multinomial logistic regression for multivariate analysis. RFS was measured from the date of surgery to the date of tumor recurrence documentation. Survival analysis was estimated using the Kaplan-Meier method, and the log-rank test was conducted for survival curve comparison. The prognostic effect of clinicopathological factors and the IHC staining of genes that regulate cell cycle was determined by univariate and multivariate (stepwise forward conditional method) Cox regression analysis. In two-sided tests, P\<0.05 was considered statistically significant. SPSS software (version 10.0; SPSS, Chicago, IL, USA) was used for all statistical analyses.

Results
=======

### Bioinformatic analysis identifies 5 critical genes and their expression levels are associated with risk groups and survival

Among the top 10 GO gene sets ([@b14-ol-0-0-9003]), 15 genes were found in ≥9 of the sets ([Table I](#tI-ol-0-0-9003){ref-type="table"}). These 15 genes were uploaded to the PID, and 6 significant pathways were predicted. Among these pathways, 'PLK1 signaling events' was the most significant. A total of 5 genes-AURKA, PLK1, CDC25C, BUB1, and TPX2- were present in this pathway ([Table II](#tII-ol-0-0-9003){ref-type="table"}). These 5 genes were also identified in ≥8 GO gene sets that were associated with cell cycle regulation identified by gene set enrichment analysis (GESA) ([Table I](#tI-ol-0-0-9003){ref-type="table"}). Therefore, these 5 genes were selected for further study.

Differences in the expression levels of these 5 genes between the AFIP high-risk group and moderate- and low-risk groups were verified. As indicated in [Fig. 2](#f2-ol-0-0-9003){ref-type="fig"}, the expression levels of the 5 genes, except for CDC25C, were significantly higher in the high-risk group compared with the moderate- and low-risk groups. Cox regression analysis revealed that patients with a high expression (Z score \>0) of AURKA, PLK1, CDC25C or TPX2 had significantly lower RFS compared with those with low expression (Z score ≤0) of these 4 genes. The differences in survival between patients with different expression levels of BUB1 were of borderline significance (P=0.082) ([Table III](#tIII-ol-0-0-9003){ref-type="table"}).

### Demographic and clinicopathological characteristics of patients enrolled for IHC study

To validate the data from microarray analysis, the expression of the 5 genes (AURKA, PLK1, CDC25C, BUB1 and TPX2) were examined by using IHC in another group of patients with GIST. The demographic data and clinicopathological features of the 141 patients are listed in [Table IV](#tIV-ol-0-0-9003){ref-type="table"}. In total, the group contained 74 men and 67 women with a mean age of 57.9 years (range, 22--89 years). The stomach constituted the most common tumor sites, and the mean tumor size was 7 cm. Under the AFIP criteria, \~35% of the patients were considered high risk.

### Association between the clinicopathological features and expression of the 5 genes in the IHC-validated patient cohort

All 141 patients had IHC staining for AURAK and BUB1. Due to limited availability of tissue slides, IHC staining for TPX2, CDC25C and PLK1 were performed in 95, 121 and 140 patients, respectively. The association between the clinicopathological characteristics and expression pattern of the 5 genes in the IHC-validated patient cohort is illustrated in [Tables V](#tV-ol-0-0-9003){ref-type="table"} and [VI](#tVI-ol-0-0-9003){ref-type="table"}. Higher AURKA expression was associated with non-gastric locations and a higher expression of BUB1, CDC25C and PLK1. Higher TPX2 expression was also associated with higher expression of BUB1, CDC25C and PLK1. Higher BUB1 IHC staining was associated with higher expression of 4 other mitotic check proteins similar to CDC25C and PLK1.

Multivariate analysis was performed in the 80 patients who had IHC for all 5 genes analyzed using multinomial logistic regression revealed that higher AURKA expression was independently associated with non-gastric locations and higher PLK1 expression. TPX2 staining was independently associated with higher PLK1 expression. BUB1 expression was independently associated with higher CDC25C and PLK1 expression. Higher CDC25C expression was independently associated with higher BUB1 expression. Higher PLK1 expression was independently associated with higher TPX2 and BUB1 expression ([Table VII](#tVII-ol-0-0-9003){ref-type="table"}).

### Prognostic effect of clinicopathological factors and expression of 5 genes on RFS

A total of 43 patients experienced recurrence, consisting of 11 locoregional relapses, 22 distant metastases and 10 multiple site recurrences. The univariate analysis indicated that the RFS was significantly affected by the tumor size, mitotic count, AFIP risk group classification, and expression level of the 5 aforementioned genes ([Table VIII](#tVIII-ol-0-0-9003){ref-type="table"}). However, only the mitotic count (P\<0.001) and expression levels of TPX2 (P=0.008), BUB1 (P=0.023), and CDC25C (P=0.017) were identified as independent unfavorable prognostic factors for RFS through multivariate analysis ([Table VIII](#tVIII-ol-0-0-9003){ref-type="table"}). The Kaplan-Meier RFS curves for these 4 factors are shown in [Fig. 3](#f3-ol-0-0-9003){ref-type="fig"}.

Discussion
==========

In the present analysis, LEA in GSEA was used to examine the genes in the leading edge subsets of the top 10 enriched gene sets and the resultant list of genes was uploaded to PID. A total of 5 genes-AURKA, PLK1, CDC25C, BUB1 and TPX2, were identified. In the patient cohort of dataset GSE8167, all but BUB1 were significant factors for poor RFS. In the IHC-validated patient cohort, only AURKA exhibited significant overexpression in non-gastric tumors when compared with gastric tumors ([Table V](#tV-ol-0-0-9003){ref-type="table"}). Although all 5 genes were considered risk factors for poor RFS based on the univariate analysis, only the expression levels of CDC25C, BUB1 and TPX2 together with mitotic count exhibited prognostic effects in the multivariate analysis.

Genes that are involved in the regulation of cell cycle have a crucial role in sarcomas. A prognostic gene expression signature-complexity index in sarcomas (CINSARC)-established by Chibon *et al* ([@b12-ol-0-0-9003]) and composed of 67 genes that are associated with chromosome integrity, mitotic control and genome complexity were able to predict metastasis outcomes. Similar findings were reported in studies of individual subtypes of sarcoma. In a study of uterine leiomyosarcomas (ULMSs) and their benign counterparts, Shan *et al* ([@b18-ol-0-0-9003]) showed that 26 of the 50 most overexpressed genes in ULMSs were involved in the regulation of mitosis and spindle function. On the other hand, our group ([@b14-ol-0-0-9003]) and Lagarde *et al* ([@b11-ol-0-0-9003]) have identified that genes that are involved in the progression or regulation of the cell cycle are strong prognostic factors of GIST recurrence. Most notably, all three studies have revealed that AURKA as one of the most crucial genes associated with ULMS and GIST recurrence ([@b11-ol-0-0-9003],[@b14-ol-0-0-9003],[@b18-ol-0-0-9003]).

In the present study, instead of random selection, LEA in GSEA was used in combination with PID to identify biologically relevant genes/pathways in GISTs. LEA in GSEA was performed to find genes that frequently appeared in the top 10 enriched gene sets. PID was used to search genes that are involved in pathways that are important in GISTs. 'PLK1 signaling events' was identified as a crucial pathway in GISTs, and 5 genes-AURKA, PLK1, CDC25, TPX2, and BUB1-in this pathway were examined.

AURKA and PLK1 are the key members of the Aurora kinase family and polo-like kinase family, respectively. Both proteins mainly function in the G2-M phase of the cell cycle. In the late G2 phase of the cell cycle, AURKA and PLK1 are recruited to the centrosome. PLK1 promotes the recruitment of AURKA that binds to centrosomin, whereas AURKA is responsible for the initial activation of PLK1 in G2 ([@b19-ol-0-0-9003]). TPX2 is a protein that interacts with AURKA and can activate AURKA in the late G2 and M phases ([@b19-ol-0-0-9003]). CDC25C is a phosphatase that is largely inactive in G2. However, mitotic entry is triggered by a steep increase in cyclin B-cyclin-dependent kinase 1 activity, which is promoted by PLK1-activated CDC25C ([@b19-ol-0-0-9003]). BUB1 is a critical component of the spindle assembly checkpoint, and the BUB1-PLK1 kinase complex promotes spindle checkpoint signaling through the phosphorylation of cell division cycle protein 20 ([@b20-ol-0-0-9003]). AURKA and PLK1 are involved in cytokinesis ([@b19-ol-0-0-9003],[@b20-ol-0-0-9003]).

In the study that examined the associations among the expressions of the 5 genes, the expression levels of PLK1, BUB1, and CDC25C were observed to be highly associated. This finding is most likely because of the interaction between PLK1 and CDC25C during mitotic entry and the formation of BUB1-PLK1 complex during spindle assembly. In addition, the expression levels of PLK1 was closely associated with that of AURKA, indicating the interactive function of these proteins in the G2-M phase ([Table VII](#tVII-ol-0-0-9003){ref-type="table"}).

Schaefer *et al* ([@b21-ol-0-0-9003]) recently identified a tumor suppressor gene called MYC-associated factor X (MAX) in GISTs. MAX is localized on chromosome 14q, one of the most frequently deleted sites in GISTs ([@b22-ol-0-0-9003]). Inactivated mutations of MAX can be found in sporadic GISTs and patients with GISTs and neurofibromatosis type 1. These inactivated mutations of MAX were also detected in micro-GISTs, indicating that it is an early event ([@b21-ol-0-0-9003]).

MAX is a binding partner of MYC and has been reported as a tumor suppressor in hereditary pheochromocytomas and small-cell lung cancer ([@b23-ol-0-0-9003],[@b24-ol-0-0-9003]). Previous studies have demonstrated that MAX may impair MYC function by impairing the ability of MYC to bind to DNA ([@b25-ol-0-0-9003],[@b26-ol-0-0-9003]). MYC is a crucial regulator of cell cycle progression. Schaefer *et al* ([@b21-ol-0-0-9003]) demonstrated that the inactivation of MAX resulted in the silencing of the p16 gene, possibly via MYC activation ([@b27-ol-0-0-9003]). In addition, MYC induces cell proliferation that is generally associated with increases in the activity of CDK2, CDK4 and CDK6 to regulate G1-S phase progression ([@b28-ol-0-0-9003]). Therefore, it was hypothesized that the inactivation of the MAX tumor suppressor occurs early in GIST progression and leads to p16 inactivation and increased proliferation by enhancing G1-S phase progression ([@b21-ol-0-0-9003]). Further cell cycle dysregulation in high-risk GISTs is most likely due to the overexpression of genes in the PLK1 signaling pathway, which may be a result of mutations of other tumor suppressor genes ([@b29-ol-0-0-9003]--[@b31-ol-0-0-9003]) with subsequent increased progression of the G2-M phase and transition to high-grade cancer ([@b22-ol-0-0-9003]).

In addition to the expression levels of the aforementioned 5 genes, the clinicopathological factors that associated with recurrence included tumor size, mitotic count and AFIP risk group classification. This finding is reasonable as all these factors are considered risk factors for recurrence. In the multivariate analysis, only mitotic count and the expression levels of TPX2, BUB1 and CDC25C were identified as independent factors for poor RFS. TPX2, BUB1 and CDC25C have been previously reported to have prognostic effects on many types of cancer but not on sarcomas or GISTs ([@b32-ol-0-0-9003]--[@b38-ol-0-0-9003]). However, unexpectedly the multivariate analysis in the present study did not reveal AURKA and PLK1 to have statistically significant effects on RFS. In a previous study by the authors, AURKA expression was associated with non-gastric tumor ([@b14-ol-0-0-9003]). In the present study, after including the expression of 4 other genes in the multivariate analysis, AURKA expression remained independently associated with non-gastric locations. This result indicated that AURKA might be responsible for a distinct and more rapidly deteriorating clinical course of non-gastric GISTs.

Other molecules involved in cell cycle regulation that may be associated with the progression of GISTs have been previously reported. For example, in an European Organization for Research and Treatment of Cancer (EORTC) study, impaired p53, p16, BCL2 and CHK2 expression was commonly detected in advanced GISTs ([@b29-ol-0-0-9003]). Alteration of genes involved in G2-M phase of cell cycle, including cyclin A, cyclin B1 and cdc2, were identified to be markers for predicting the aggressive behavior of GISTs in a Japanese study ([@b39-ol-0-0-9003]). These studies further supported the important roles of cell cycle regulators in GISTs.

There are limitations of statistical analysis in the present study. Due to limited availability of tissue slides, only AURKA and BUB1 IHC staining were done in all 141 patients. IHC staining for TPX2, CDC25C and PLK1 were done in 95, 121 and 140 patients, respectively. This definitely jeopardized the final analysis of this study. A total of 43 patients experienced recurrence. This relatively low number of recurrence may limit the statistical power of the study. Hopefully, there may be a larger cohort of patients through collaboration of multiple hospitals for further validation in the future. Another issue is that the possibility of multicollinearity ([@b40-ol-0-0-9003]) when using Cox regression model for multivariate analysis cannot be ruled out, since there is a high number of interactions between all the genes in cell cycle regulation. Nonetheless, CDC25C and BUB1, the two genes identified as independent prognostic factors, were also the only two genes that could be found in the GESA GO gene set 'regulation of mitosis' ([Table I](#tI-ol-0-0-9003){ref-type="table"}), indicating their critical roles in the disease. This result demonstrated that the present study was still able to identify important genes through Cox regression analysis.

In conclusion, through bioinformatics analysis and IHC validation, 5 genes-AURKA, PLK1, CDC25C, BUB1 and TPX2-in the PLK1 signaling pathway were identified as risk factors for poor prognosis of GIST. AURKA was significantly overexpressed in non-gastric GISTs. All 5 genes were considered as risk factors for poor RFS based on the univariate analysis. The mitotic count and expression levels of CDC25C, BUB1 and TPX2 retained prognostic effects in the multivariate analysis. The results of the present study indicated that the PLK1 signaling pathway might be crucial in the disease progression of GISTs. Furthermore, genes in this pathway may serve as predictive markers for adjuvant therapy.
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![Examples of positive immunostaining of 5 genes (two figures are provided for each gene): (A) AURKA; (B) BUB1; (C) CDC25C; (D) PLK1; (E) TPX2. AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; PLK1, polo like kinase 1.](ol-16-03-3070-g00){#f1-ol-0-0-9003}

![Comparison of expression level (indicated by Z scores) of 5 genes, AURKA, PLK1, CDC25C, BUB1 and TPX2, between the AFIP high- and moderate-/low-risk groups in 32 gastrointestinal stromal tumors (GIST) cases in the Japanese cohort using the t-test. With the exception of CDC25C, the expression level of the other 4 genes were significantly higher in the high-risk group compared with the moderate-/low-risk group. \*P\<0.05. AFIP, Armed Forces Institute of Pathology; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C; cell division cycle 25C; PLK1, polo like kinase 1.](ol-16-03-3070-g01){#f2-ol-0-0-9003}

![Kaplan-Meier plot of recurrence-free survival of patients with gastrointestinal stromal tumors according to: (A) Mitotic count (n=141); (B) TPX expression level (n=95); (C) BUB1 expression level (n=141); and (D) CDC25C expression level (n=121). The P-values for survival comparison, obtained by the log-rank test, were all \<0.05. RFS, recurrence-free survival; TPX2, targeting protein for Xk; BUB1, budding uninhibited by benzimidazoles 1 homolog lp2; CDC25C; cell division cycle 25C.](ol-16-03-3070-g02){#f3-ol-0-0-9003}

###### 

Identification of 15 genes by GSEA and the presence of these genes in the top 10 enriched gene sets.

                                  KNTC1   TTK   NEK2   BUB1^[a](#tfn2-ol-0-0-9003){ref-type="table-fn"}^   BIRC5   AURKA^[a](#tfn2-ol-0-0-9003){ref-type="table-fn"}^   MAD2L1   ZWINT   ANLN   PLK1^[a](#tfn2-ol-0-0-9003){ref-type="table-fn"}^   KIF2C   KIF11   KIF15   TPX2^[a](#tfn2-ol-0-0-9003){ref-type="table-fn"}^   CDC25C^[a](#tfn2-ol-0-0-9003){ref-type="table-fn"}^
  ------------------------------- ------- ----- ------ --------------------------------------------------- ------- ---------------------------------------------------- -------- ------- ------ --------------------------------------------------- ------- ------- ------- --------------------------------------------------- -----------------------------------------------------
  Mitosis                         V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  Cell cycle process              V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  Mitotic cell cycle              V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  M phase of mitotic cell cycle   V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  Cell cycle phase                V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  M phase                         V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  Microtubule cytoskeleton        V       V     V      V                                                   V       V                                                                            V                                                   V       V       V       V                                                   
  Cell cycle GO 0007049           V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V
  Regulation of mitosis           V       V     V      V                                                   V                                                            V        V       V                                                                                                                                      V
  Non-membrane bound organelle    V       V     V      V                                                   V       V                                                    V        V       V      V                                                   V       V       V       V                                                   V

'V' indicates the presence of gene in the GSEA gene sets.

Genes in the 'PLK1 signaling events' identified by Pathway Interaction Database; GSEA, gene set enrichment analysis; ANLN, anillin actin binding protein; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; KIF11, kinesin family member 11; KIF15, kinesin family member 15; KNTC1, kinetochore associated 1; MAD2L1, mitotic arrest deficient 2 like 1; NEK2, NIMA related kinase 2; TPX2, targeting protein for Xklp2; TTK, phosphotyrosine picked threonine kinase; ZWINT, ZW10 interacting kinetochore protein.

###### 

Pathways identified by the Pathway Interaction Database.

  Pathway name                         Biomolecules in the group            P-value
  ------------------------------------ ------------------------------------ ------------------------------------------------------
  PLK1 signaling events                AURKA, BUB1, CDC25C, PLK1 and TPX2   2.16×10^−9a^
  Aurora B signaling                   AURKA, BIRC5, BUB1 and KIF2C         2.05×10^−7a^
  Aurora A signaling                   AURKA, BIRC5 and TPX2                8.55×10^−6a^
  FOXM1 transcription factor network   BIRC5, NEK2 and PLK1                 2.16×10^−5a^
  ATR signaling pathway                CDC25C and PLK1                      0.00109^[a](#tfn3-ol-0-0-9003){ref-type="table-fn"}^
  p73 transcription factor network     BUB1 and PLK1                        0.00474^[a](#tfn3-ol-0-0-9003){ref-type="table-fn"}^

P\<0.05 (hypergeometric distribution). AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; TPX2, targeting protein for Xklp2; PLK1, polo like kinase 1.

###### 

Univariate analysis of the prognostic effect of expression level of the 5 genes on recurrence-free survival.

  Gene     Median survival, months (95% CI)   HR        Univariate analysis, 95% CI   P-value
  -------- ---------------------------------- --------- ----------------------------- ----------------------------------------------------
  AURKA                                                                               
    Low    Not reached                        1                                       0.013^[a](#tfn4-ol-0-0-9003){ref-type="table-fn"}^
    High   56.000 (21.635--90.365)            7.242     1.527--34.345                 
  PLK1                                                                                
    Low    Not reached                        1                                       0.006^[a](#tfn4-ol-0-0-9003){ref-type="table-fn"}^
    High   53.000 (10.278--95.722)            8.727     1.847--41.221                 
  CDC25C                                                                              
    Low    Not reached                        1                                       0.049^[a](#tfn4-ol-0-0-9003){ref-type="table-fn"}^
    High   53.000 (6.515--99.485)             3.685     1.008--13.475                 
  BUB1                                                                                
    Low    Not reached                        1                                       0.082
    High   53.000 (7.269--98.731)             112.965   0.549--23248.895              
  TPX2                                                                                
    Low    Not reached                        1                                       0.001^[a](#tfn4-ol-0-0-9003){ref-type="table-fn"}^
    High   28.000 (16.500--39.500)            14.204    2.994--67.390                 

P\<0.05, univariate Cox regression analysis. AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; CI, confidence interval; HR, hazard ratio; TPX2, targeting protein for Xklp2.

###### 

Clinicopathological characteristics of 141 patients with gastrointestinal stromal tumors.

  Clinicopathological features    Patients, n (%)
  ------------------------------- -----------------
  Mean age (years, mean ± SD)     57.9±12.6
    Sex (M:F)                     74:67
  Location                        
    Gastric                       83 (58.9)
    Non-gastric                   58 (41.1)
    Tumor size (cm, mean ± SD)    7.06±4.93
  Mitotic count, HPF              
    \<5/50                        89 (63.1)
    5-10/50                       16 (11.3)
    \>10/50                       36 (25.5)
  AFIP risk                       
    None                          10 (7.1)
    Very low                      28 (19.9)
    Low                           27 (19.1)
    Moderate                      27 (19.1)
    High                          49 (34.8)
  AURKA immunostaining            
    Low                           73 (51.8)
    High                          68 (48.2)
  TPX2 immunostaining             
    Low                           64 (67.4)
    High                          31 (32.6)
  BUB1 nuclear immunostaining     
    Low                           64 (45.4)
    High                          77 (54.6)
  CDC25C nuclear immunostaining   
    Low                           55 (45.5)
    High                          66 (54.5)
  PLK1 immunostaining             
    Low                           79 (56.4)
    High                          61 (43.6)

AFIP, Armed Forces Institute of Pathology; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; F, female; HPF, high-power fields; M, male; SD, standard deviation.

###### 

Association of IHC intensity of five genes with clinicopathological characteristics of patients with gastrointestinal stromal tumors.

                       *AURKA* score, (%)   *TPX2* score, (%)                                    *BUB1* score, (%)   *CDC25C* score, (%)   *PLK1* score, (%)                                                   
  -------------------- -------------------- ---------------------------------------------------- ------------------- --------------------- ------------------- ----------- ----------- ----------- ----------- -----------
  Age                                                                                                                                                                                                          
    \<60               38 (46.3)            44 (53.7)                                            34 (63.0)           20 (37.0)             37 (45.1)           45 (54.9)   31 (41.9)   43 (58.1)   48 (58.5)   34 (41.5)
    ≥60                35 (59.3)            24 (40.7)                                            30 (73.2)           11 (26.8)             27 (45.8)           32 (54.2)   24 (51.1)   23 (48.9)   31 (53.4)   27 (46.6)
    P-value                                 0.128                                                                    0.293                                     0.940                   0.323                   0.550
  Sex                                                                                                                                                                                                          
    Male               35 (47.3)            39 (52.7)                                            35 (67.3)           17 (32.7)             33 (44.6)           41 (55.4)   23 (39.0)   36 (61.0)   40 (54.1)   34 (45.9)
    Female             38 (56.7)            29 (43.3)                                            29 (67.4)           14 (32.6)             31 (46.3)           36 (53.7)   32 (51.6)   30 (48.4)   39 (59.1)   27 (40.9)
    P-value                                 0.264                                                                    0.989                                     0.842                   0.163                   0.549
  Location                                                                                                                                                                                                     
    Gastric            53 (63.9)            30 (36.1)                                            36 (62.1)           22 (37.9)             36 (43.4)           47 (56.6)   33 (47.8)   36 (52.2)   43 (52.4)   39 (47.6)
    Non-gastric        20 (34.5)            38 (65.5)                                            28 (75.7)           9 (24.3)              28 (48.3)           30 (51.7)   22 (42.3)   30 (57.7)   36 (62.1)   22 (37.9)
    P-value                                 0.001^[a](#tfn6-ol-0-0-9003){ref-type="table-fn"}^                       0.168                                     0.565                   0.546                   0.258
  Tumor size, cm                                                                                                                                                                                               
    \<5                35 (59.3)            24 (40.7)                                            32 (76.2)           10 (23.8)             29 (49.2)           30 (50.8)   31 (56.4)   24 (43.6)   37 (63.8)   21 (36.2)
    5--10              25 (48.1)            27 (51.9)                                            23 (63.9)           13 (36.1)             26 (50.0)           26 (50.0)   17 (38.6)   27 (61.4)   28 (53.8)   24 (46.2)
    \>10               13 (43.3)            17 (56.7)                                            9 (52.9)            8 (47.1)              9 (30.0)            21 (70.0)   7 (31.8)    15 (68.2)   14 (46.7)   16 (53.3)
    P-value                                 0.288                                                                    0.193                                     0.161                   0.077                   0.275
  Mitotic count, HPF                                                                                                                                                                                           
    \<5/50             45 (50.6)            44 (49.4)                                            43 (71.7)           17 (28.3)             44 (49.4)           45 (50.6)   39 (49.4)   40 (50.6)   53 (60.2)   35 (39.8)
    ≥5/50              28 (53.8)            24 (46.2)                                            21 (60.0)           14 (40.0)             20 (38.5)           32 (61.5)   16 (38.1)   26 (61.9)   26 (50.0)   26 (50.0)
    P-value                                 0.706                                                                    0.242                                     0.207                   0.236                   0.238
  AFIP risk                                                                                                                                                                                                    
    Low                38 (58.5)            27 (41.5)                                            31 (70.5)           13 (29.5)             32 (49.2)           33 (50.8)   32 (56.1)   25 (43.9)   37 (57.8)   27 (42.2)
    Moderate           14 (51.9)            13 (48.1)                                            13 (72.2)           5 (27.8)              15 (55.6)           12 (44.4)   9 (36.0)    16 (64.0)   17 (63.0)   10 (37.0)
    High               21 (42.9)            28 (57.1)                                            20 (60.6)           13 (39.4)             17 (34.7)           32 (65.3)   14 (35.9)   25 (64.1)   25 (51.0)   24 (49.0)
    P-value                                 0.256                                                                    0.586                                     0.152                   0.084                   0.576

P\<0.05 (χ^2^ or Fisher\'s exact test). AFIP, Armed Forces Institute of Pathology; HPF, high-power fields; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; PLK1, polo like kinase 1. All 141 patients have IHC staining of AURAK and BUB1. Due to limited availability of tissue slides, IHC staining for TPX2, CDC25C and PLK1 were performed in 95, 121 and 140 patients, respectively.

###### 

Association of IHC intensity between five genes.

                   *AURKA* score, (%)   *TPX2* score, (%)   *BUB1* score, (%)   *CDC25C* score, (%)   *PLK1* score, (%)                                                                                                                                        
  ---------------- -------------------- ------------------- ------------------- --------------------- ------------------- ---------------------------------------------------- ----------- ------------------------------------------------------ ------------ ------------------------------------------------------
  *AURKA* score                                                                                                                                                                                                                                                
    Low            --                   --                  29 (70.7)           12 (29.3)             41 (56.2)           32 (43.8)                                            35 (56.5)   27 (43.5)                                              50 (69.4)    22 (30.6)
    High           --                   --                  35 (64.8)           19 (35.2)             23 (33.8)           45 (66.2)                                            20 (33.9)   39 (66.1)                                              29 (42.6)    39 (57.4)
    P-value        --                   --                                      0.542                                     0.008^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^               0.013^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^                  0.001^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^
  *TPX2* score                                                                                                                                                                                                                                                 
    Low            --                   --                  --                  --                    34 (53.1)           30 (46.9)                                            28 (51.9)   26 (48.1)                                              41 (64.1%)   23 (35.9)
    High           --                   --                                                            7 (22.6)            24 (77.4)                                            6 (23.1)    20 (76.9)                                              6 (19.4)     25 (80.6)
    P-value        --                   --                  --                  --                                        0.005^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^               0.015^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^                  \<0.001^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^
  *BUB1* score                                                                                                                                                                                                                                                 
    Low            --                   --                  --                  --                                        --                                                   37 (66.1)   19 (33.9)                                              51 (79.7)    13 (20.3)
    High           --                   --                  --                  --                    --                  --                                                   18 (27.7)   47 (72.3)                                              28 (36.8)    48 (63.2)
    P-value        --                   --                  --                  --                    --                  --                                                               \<0.001^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^                \<0.001^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^
  *CDC25C* score                                                                                                                                                                                                                                               
    Low            --                   --                  --                  --                    --                  --                                                   --                                                                 41 (75.9)    13 (24.1)
    High                                --                  --                  --                    --                  --                                                   --          --                                                     26 (39.4)    40 (60.6)
    P-value                             --                  --                  --                    --                  --                                                   --                                                                              \<0.001^[a](#tfn7-ol-0-0-9003){ref-type="table-fn"}^

P\<0.05 (χ^2^ or Fisher\'s exact test). AFIP, Armed Forces Institute of Pathology; HPF, high-power fields; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; PLK1, polo like kinase.

###### 

Multivariate analysis of association of clinicopathological characteristics with IHC intensity of five genes in 80 GIST patients.

                                         AURKA score          TPX2 score   BUB1 score           CDC25C score   PLK1 score                                                                     
  -------------------------------------- -------------------- ------------ -------------------- -------------- -------------------- ------- -------------------- ------- -------------------- -------
  Age (\<60/≥60)                                              NS                                NS                                  NS                           NS                           NS
  Gender (Male/Female)                                        NS                                NS                                  NS                           NS                           NS
  Location (Gastric/Non-gastric)         4.91 (2.02--11.94)   \<0.001                           NS                                  NS                           NS                           NS
  Tumor size (\<5 cm/5-10 cm/\>10 cm)                         NS                                NS                                  NS                           NS                           NS
  Mitotic count (\<5/50 HPF/≥5/50 HPF)                        NS                                NS                                  NS                           NS                           NS
  AFIP risk (Low/Moderate/High)                               NS                                NS                                  NS                           NS                           NS
  AURKA score (Low/High)                                      --                                NS             1.73 (0.54--5.58)    0.358   1.29 (0.45--3.73)    0.633   1.67 (0.50--5.56)    0.405
  TPX2 score (Low/High)                                       NS                                --             2.21 (0.59--8.26)    0.24    1.56 (0.46--5.34)    0.476   3.76 (1.05--13.51)   0.042
  BUB1 score (Low/High)                  1.62 (0.63--4.16)    0.317        2.36 (0.62--8.94)    0.206                               --      3.38 (1.06--10.74)   0.039   7.42 (2.27--24.29)   0.001
  CDC25C score (Low/High)                1.38 (0.57--3.34)    0.481        1.58 (0.46--5.42)    0.463          3.37 (1.05--10.76)   0.041                        --      2.90 (0.88--9.58)    0.081
  PLK1 score (Low/High)                  3.79 (1.41--10.18)   0.008        3.92 (1.07--14.35)   0.039          7.41 (2.26--24.34)   0.001   2.84 (0.87--9.30)    0.085                        --

Multinomial logistic regression was used for statistical analysis. AFIP, Armed Forces Institute of Pathology; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; HPF, high-power fields; PLK1, polo like kinase 1; NS, not significant.

###### 

Univariate and multivariate analyses of the prognostic effects of clinicopathological factors on recurrence-free survival.

                         Median survival                    Univariate analysis                                                           Multivariate analysis                   
  ---------------------- ------------------------- -------- --------------------- ------------------------------------------------------- ----------------------- --------------- -------------------------------------------------------
  Age                                                                                                                                                                             
    \<60 (n=82)          124.97 (88.15--161.78)    1                              0.580                                                                                           
    ≥60 (n=59)           Not achieved              1.189    0.644--2.194                                                                                                          
  Sex                                                                                                                                                                             
    Female (n=67)        Not achieved              1                              0.104                                                                                           
    Male (n=74)          124.97 (52.27--197.66)    1.672    0.900--3.104                                                                                                          
  Location                                                                                                                                                                        
    Gastric (n=83)       Not achieved              1                              0.262                                                                                           
    Non-gastric (n=58)   110.27 (66.15--154.39)    1.44     0.762--2.721                                                                                                          
  Tumor size, cm                                                                                                                                                                  
    \<5 (n=59)           124.97 (104.1--145.83)    1                              \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^                                           \>0.05
    5--10 (n=52)         99.86 (59.64--140.10)     4.899    1.646--14.583                                                                                                         
    \>10 (n=30)          21.67 (15.17--28.17)      18.436   6.324--53.740                                                                                                         
  Mitotic count. HPF                                                                                                                                                              
    \<5 /50 (n=89)       Not achieved              1                              \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^   1                                       \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^
    ≥5 /50 (n=52)        33.97 (15.05--52.88)      12.086   5.094--28.679                                                                 9.207                   2.958--28.661   
  AFIP risk                                                                                                                                                                       
    Low (n=65)           Not achieved              1                              \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^                                           \>0.05
    Moderate (n=27)      Not achieved              12       1.401--102.793                                                                                                        
    High (n=49)          30.80 (17.57--44.04)      56.914   7.791--415.752                                                                                                        
  AURKA score                                                                                                                                                                     
    Low (n=73)           Not achieved              1                              0.040^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^                                             \>0.05
    High (n=68)          99.87 (53.50--146.23)     1.904    1.031--3.517                                                                                                          
  TPX2 score                                                                                                                                                                      
    Low (n=64)           124.97 (108.87--141.07)   1                              0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^     1                                       0.008^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^
    High (n=31)          57.37 (22.95--91.78)      3.895    1.800--8.431                                                                  4.016                   1.440--11.196   
  BUB1 score                                                                                                                                                                      
    Low (n=64)           126.83 (122.04--131.63)   1                              \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^   1                                       0.023^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^
    High (n=77)          55.80 (39.99--71.61)      5.038    2.419--10.494                                                                 4.979                   1.247--19.870   
  CDC25C score                                                                                                                                                                    
    Low (n=55)           Not achieved              1                              \<0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^   1                                       0.017^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^
    High (n=66)          82.20 (22.76--141.64)     6.484    2.786--15.091                                                                 5.154                   1.344--19.762   
  PLK1 score                                                                                                                                                                      
    Low (n=79)           126.83 (122.23--131.43)   1                              0.001^[a](#tfn10-ol-0-0-9003){ref-type="table-fn"}^     1                                       \>0.05
    High (n=61)          54.40 (35.35--73.45)      3.132    1.615--6.071                                                                                                          

Univariate and multivariate Cox regression analyses were performed.

P\<0.05. AFIP, Armed Forces Institute of Pathology; HR, hazard ratio; CI, confidence interval; AURKA, aurora kinase A; BUB1, budding uninhibited by benzimidazoles 1 homolog; CDC25C, cell division cycle 25C; HPF, high-power fields; PLK1, polo like kinase 1.
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